The fundamental principle of precision oncology is centralized on the identification of therapeutically exploitable targets that provides individual patients with cancer an opportunity to make informed decisions on a personalized level. To facilitate and adopt such concepts within clinical practice, we have initiated a nationwide, multi-institutional precision oncology screening program to examine and enroll patients into the most appropriate clinical trial based on their tumor’s unique molecular properties. To determine the prevalence of essential major driver mutations and to explore their dynamic associations at both molecular and pathway levels, we present a comprehensive overview on the genomic properties of East Asian patients with cancer. We further delineate the extent of genomic diversity as well as clinical actionability in patients from Western and Eastern cultures at the pan-cancer and single-tumor entity levels. To support fellow oncology communities in future investigations involving large-scale analysis, all data have been made accessible to the public (https://kmportal.or.kr). SIGNIFICANCE: We present a comprehensive overview of molecular properties of East Asian pan-can-cer patients and demonstrate significant diversity in terms of genomic characteristics as well as clinical utility compared with patients with European ancestry. The results of this study will lay the groundwork for designing personalized treatments in the clinical setting.
Bibliographical noteFunding Information:
Y.H. Kim reports grants from the Ministry of Health and Welfare, Korea, during the conduct of the study. No disclosures were reported by the other authors.
This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (HI17C2206 to K.H. Park and Y.H. Kim), a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT; NRF-2020R1F1A1076444 to J.K. Sa), the Bio and Medical Technology Development Program of the NRF funded by the Korean government (MSIT; 2020M3A9D8038658 to J.K. Sa), and a Korea Evaluation Institute of Industrial Technology grant funded by the Korean government (MSIT; 20009125 to J.K. Sa).
© 2021 The Authors; Published by the American Association for Cancer Research.
ASJC Scopus subject areas